Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B)

Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B)
Conditions: Esophageal Carcinoma; Gastric Cancer (Diagnosis); Colorectal Adenocarcinoma; Appendiceal Adenocarcinoma; Small Bowel Adenocarcinoma; Hepatobiliary Carcinoma in Situ

Interventions: Drug: Paclitaxel Q2W; Drug: Paclitaxcel Q3W

Sponsors: University of California, Irvine

**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 1, 2026Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Comments